GH Research (GHRS)
NASDAQ:GHRS
Want to see GHRS full AI Analyst Report?
GHRS Stock Chart & Stats
$18.34
-$0.22(-2.41%)
At close: 4:00 PM EST
$18.34
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$8.75 - $24.66
Previous CloseN/A
Volume14.35K
Average Volume (3M)172.07K
Market Cap
$1.17B
Enterprise Value$921.03M
Total Cash (Recent Filing)$280.71M
Total Debt (Recent Filing)$512.00K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,029,396
10 Day Avg. Volume103,362
30 Day Avg. Volume172,068
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.56K
Enterprise Value/Ebitda-18.26
Forecast
1Y Price Target
$41.29Price Target Upside125.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyEarly trial data showed rapid symptom improvement, durable benefits, high remission rates and an acceptable safety profile in treatment-resistant depression, supporting the therapy's clinical potential.
Commercial And Delivery AdvantagesAn inhaled aerosol device that produces an ultra-short psychoactive experience with infrequent dosing could enable higher patient throughput, simpler clinic workflows and stronger commercial appeal.
Regulatory ClearanceFDA lifted the clinical hold on the investigational inhaled drug, clearing the way for regulatory discussions and progression toward a pivotal Phase 3 program.
Bears Say
Execution And Financing RiskAdvancement requires completion of a bridging study with the proprietary device and assumes future financing, introducing execution risk and potential dilution for investors.
Regulatory Alignment RiskLack of a formal agreement with regulators on pivotal trial design creates uncertainty that could delay approvals and complicate development planning.
Trial Initiation RiskClinical sites will not be activated until the Phase 3 protocol is finalized with the FDA, increasing the risk of delays to trial start and enrollment timelines.
GH Research News
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $8.75 and its highest was $24.66 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $1.17B.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is May 07, 2026 which is in 13 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Mar 05, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.264 by $0.034.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.29.
How many shares outstanding does GH Research have?
GH Research has 62,029,396 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.264. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.29 (125.11% Upside)
$41.29 (125.11% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.53%
12-Months-Change
Fundamentals
Return on Equity
-16.30%
Trailing 12-Months
Asset Growth
53.09%
Trailing 12-Months
Company Description
GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$41.29
▲(125.11% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
4.22% Mutual Funds
<0.01% Other Institutional Investors
94.84% Public Companies and Individual Investors